3Mitsui T, Kunishige M, Ichimiya M, et al. Beneficial Effect of Tacrolimus on Myasthenia Gravis with Thymoma[J]. Neurologist (S1074 - 7931 ), 2007,13 (2) : 83 -86.
4Ponseti JM, Azem J, Fort JM, et al. Experience with Starting Taerolimus Post Operati Vely after Transsternal Extended Thymectomy in Patients with Myasthenia Gravis[J]. Curr Med Res Opin(S0300-7995), 2006, 22(5):885-895.
5Shimojima Y,Matsuda M,Gono T,et al. Tacrolimus in Refractory Patients with Myasthenia Gravis: Coadministration and Tapering of Oral Prednisolone[J]. J Clin Neurosci(S0967 - 5868), 2006,13 ( 1 ) : 39 - 44.
6Ponseti JM, Azem J, Fort JM, et al. Benefits of FK506 (Tacrolimus) for Residual, Cyclosporin-and Prednisone-resistant Myasthenia Gravis: One-year Follow-up of an Open-label Study [J]. Clin Neurol Neurosurg (S0303 - 8467), 2005,107 (3) : 187 - 190.
7Yoshikawa H, Mabuchi K, Yasukawa Y, et al. Lowdose Tacrolimus for Intractable Myasthenia Gravis[J]. J Clin Neurosci(S0967-5868) ,2002,9(6):627-628.
8Utsugisawa K, Nagane Y, Yonezawa H, et al. Effects of FK506 on Myasthenia Gravis Patients with High Interleukin-2 Productivity in Peripheral Blood Mononuclear Cells[J]. Muscle Nerve(S0148 - 639X), 2003,27(2) : 245-248.
9Yoshikawa H, Mabuchi K, Yasukawa Y, et al. Lowdose Tacrolimus for Intractable Myasthenia Gravis[J]. J Clin Neurosci(S0967- 5868) ,2002,9(6) :627-628.
10Konishi T, Yoshiyama Y, Takamori M, et al. Clinical Study of FK506 in Patients with Myasthenia Gravis [J]. Muscle Nerve(S0148-639X) ,2003,28(5):570- 574.
二级参考文献41
1[1]Dumont FJ. FK506, an immunosuppressant targeting calcineurin function[J]. Curr Med Chem, 2000, 7(7): 731.
2[2]Cho CS, Chang Z, Elkahwaji J, et al. Rapamycin antagonizes cyclosporine A - and tacrolimus(FK506) - mediated augmentation of linker for activation of T cell expression in T cell[J]. Int Immunol, 2003, 15 ( 11 ): 1369.
3[3]Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cell by immunosuppressive drugs[J]. Clin Exp Immunol, 2002, 128(2): 255.
4[4]Platz KP, Mueller AR, Spree E, et al. Liver transplantation foralcoholic cirrhosis[J]. Transpl Int, 2000,13 (Suppl 1): S127.
5[6]Martins L, Henriques AC, Dias L, et al. Conversion to tacrolimus in case problem kidney transplant recipients under cyclosporinebased immunosuppression[J]. Transplant Proc, 2000, 32(8): 2636.
6[7]Thorp M, Demattos A, Bennett W, et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol[J]. Transplantation, 2000, 69(6): 1218.
7[8]Amitage JM, Kormos RL, Fung J. The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation[J]. Transplant Proc, 1991, 23 (28): 3054.
8[9]Von Steinbuchel N, Limm H, Leopold C, et al. Assessment of health - related quality - life in patients after heart transplantation under therapy with tacrolimus of cyclosporine [ J ]. Transpl Int,2000, 13(Suppl 1): S609.
9[10]David Grant on Behalf of the International Intestinal Transplant Registry. Current results of intestinal transplantation [J ]. Lancet,1996, 347: 1801.
10[11]Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft- versus -host disease with sysaenic administration of FK506 and cotisosteroids [J].Cornea, 2001, 20(4): 430.
